Skip to main content
. Author manuscript; available in PMC: 2014 Jan 24.
Published in final edited form as: Cancer Chemother Pharmacol. 2009 Feb 17;64(4):803–810. doi: 10.1007/s00280-009-0931-y

Table 6.

Patient characteristics with stable disease

Time to
progression
(weeks)
Total # of
patients
Most common tumor
types
Most
common
dose
levels
Reasons to be off
protocol other than PD
(AE/Noncompliance)
9 5 Melanoma/liposarcoma 5 and 11 2/2
12 9 Melanoma/ appendiceal cancer/ head and neck cancer/ NSCLC/ RCC 2A and 1 3/3
15 3 Melanoma/ head and neckcancer/ appendiceal cancer 4,7,1A 2/0
18 3 Melanoma/ small cell lung cancer 3,10, 2A 0/1
22 1 Melanoma 2A 0/0